KMDA
Kamada LtdstockNASDAQ
kamada ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. the company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce alpha-1 antitrypsin (aat) in a highly-purified, liquid form, as well as other plasma-derived proteins. aat is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. the company's flagship product is glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived aat product approved by the u.s. food and drug administration. kamada markets glassia in the u.s. through a strategic partnership with baxter international. in addition to glassia, kamada has a product line of nine other pharmaceutical products that are marketed through distributor
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 8.09 | 2026-11-13 | -2.72% | 0.479 |
| 1M | 7.85 | 2026-10-20 | +0.26% | 1.576 |
| 3M | 8.02 | 2026-08-20 | -1.87% | 1.290 |
| 1Y | 6.68 | 2025-11-20 | +17.81% | 1.055 |
| 2Y | 5.82 | 2024-11-20 | +35.22% | — |
| 5Y | 5.60 | 2021-11-19 | +40.54% | 0.712 |
Kamada Ltd (NASDAQ:KMDA) stock price today is $7.87, and today's volume is 158,516. KMDA is down 2.478% today. The 30 day average volume is 106,565. KMDA market cap is $454.35M with 57.73M shares outstanding.